Phico Therapeutics Ltd., Bertarelli Building, Bourn Hall, High Street, Bourn, Cambridgeshire CB23 2TN, U.K.
Emerg Top Life Sci. 2021 Nov 12;5(5):637-641. doi: 10.1042/ETLS20210147.
Interest in phage-based therapeutics is increasing, at least in part due to the need for new treatment options for infections caused by antibiotic-resistant bacteria. It is possible to use wild-type (WT) phages to treat bacterial infections, but it is also possible to modify WT phages to generate therapeutics with improved features. Here, we will discuss features of Phico Therapeutics' SASPject technology, which modifies phages for use as targetable nano-delivery vehicles (NDV), to introduce antibacterial Small Acid Soluble Spore Protein (SASP) genes into specific target bacteria.
人们对噬菌体疗法的兴趣日益增加，至少部分原因是需要新的治疗方案来应对由抗生素耐药菌引起的感染。虽然可以使用野生型（WT）噬菌体来治疗细菌感染，但也可以对 WT 噬菌体进行修饰，以生成具有改良特性的治疗药物。在这里，我们将讨论 Phico Therapeutics 的 SASPject 技术的特点，该技术对噬菌体进行修饰，将其用作靶向性纳米递药载体（NDV），将具有抗菌作用的小分子酸溶性孢子蛋白（SASP）基因引入特定靶细菌。
